Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Michael Cecchini, Mary Jo Pilat, Nataliya Uboha, Nilofer S. Azad, May Cho, Elizabeth J. Davis, Jordi Rodon Ahnert, Gabriel Tinoco, Geoffrey I. Shapiro, Simon Khagi, Benjamin Powers, Kristen Spencer, Roman Groisberg, Jan Drappatz, Li Chen, Biswajit Das, Xun Bao, Jing Li, Azeet Narayan, Dennis Vu, Abhijit Patel, Monica Niger, Deborah Doroshow, Diane Durecki, Scott A. Boerner, Ranjit Bindra, Percy Ivy, Derek Shyr, Yu Shyr, Patricia M. LoRusso
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Cancer
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Internet